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Abstract
Background: Resistance to macrolide, lincosamide, and streptogramin B (MLSB) antibiotics is mediated by erm and msrA genes in
Staphylococcus aureus. The expression of these genes can lead to three phenotypes, namely constitutive resistance (cMLSB), inducible
resistance (iMLSB), which are resistant to macrolide, lincosamide, and streptogramin B antibiotics, and MSB phenotype, which is re-
sistant only to macrolide and streptogramin B. Inducible clindamycin resistance is an important concern because it is not detected
in routine laboratory tests.
Objectives: The aim of this study was to determine the frequency of MLSB phenotypes and genotypes among 215 clinical isolates of S.
aureus and then, examine their resistance to antibacterial agents, which is recommended for methicillin-resistant S. aureus (MRSA)
isolates.
Methods: Two hundred and fifteen non-repetitive clinical isolates of S. aureus were collected. Resistance to antibacterial agents was
determined by disk diffusion and E-test methods. Susceptibility to clindamycin and erythromycin was tested by D-test. All isolates
were screened by PCR for the presence of nucA, mecA, ermA, ermB, ermC, and msrA genes.
Results: The prevalence of iMLSB, cMLSB and MSB phenotypes among all the isolates was determined as 10.69%, 34.42%, and 0%, re-
spectively. In our study, iMLSB was prevalent more in methicillin susceptible S. aureus (MSSA) (11.71%) than MRSA (9.19%) isolates (P =
0.557). In contrast, the rate of cMLSB was significantly higher in MRSA (79.31%) than MSSA (3.90%) isolates (P = 0.000). No MSB phe-
notype was detected in our study. The most prevalent genes were ermC and ermA with 39% and 21.5% frequencies, respectively. Six
isolates showed D phenotype, while the PCR results of erm genes were negative. All 215 isolates of S. aureus were negative for the
presence of ermB and msrA genes.
Conclusions: The rate of iMLSB in S. aureus isolates is relatively high in the Northwest Iran. Since isolates with inducible resistance
may mutate and change to constitutive resistance, to prevent clinical treatment failure, D-test should be performed along with
routine antibiotic susceptibility tests. In this study, ermC gene was the predominant genetic determinant for the expression of MLSB
resistance. This predominance is probably due to the spread of distinctive clones (which carry ermC gene) in our region.
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1. Background
Staphylococcus aureus is one of the most common and
important pathogens, accounting for diverse nosocomial
and community acquired infections. The bacterium has
potentiality to cause three types of disorders in human:
superficial, toxin mediated, and lethal-systemic infections
(1). The serious concern about this bacterium is devel-
opment of antibiotic resistance, especially against methi-
cillin, the so-called methicillin resistant S. aureus (MRSA)
(2, 3). The emergence of MRSA has left with very few antibi-
otic alternatives to treat S. aureus-related infections, which
has caused renewed interest in the usage of macrolide, lin-
cosamide, and streptogramin B (MLSB) antibiotics against
S. aureus infections (2, 4). Though these antibiotics differ
structurally, they act in a similar way. They inhibit protein
synthesis via binding to large subunit of ribosome (4, 5).
Among these antibiotics, clindamycin is preferred because
of its excellent pharmacokinetic properties (6, 7). Unfor-
tunately, mistreatments with MLSB antibiotics have caused
an unusual increase in the rate of resistance to these antibi-
otics leading to clinical treatment failure (8).
Three main mechanisms have been elucidated for
MLSB antibiotics resistance in staphylococci: target site
modification by a methylase enzyme encoded by erm
genes, including ermA, ermB, ermC, or ermF (ermA and ermC
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are more common); Macrolide eﬄux pump encoded by
msrA or msrB genes; and inactivation of lincosamides due
to lincosamide nucleotidyl transferase enzyme which is
encoded by inuA gene (9, 10).
In vitro, S. aureus isolates with inducible resistance
are resistant to erythromycin but appear susceptible
to clindamycin. In this situation, therapy with clin-
damycin may be selective for constitutive erm mutants,
which can lead to clinical treatment failure (6, 8); but,
erythromycin-resistant staphylococci should not be as-
sumed as clindamycin-resistant (11). Since isolates with
msrA-mediated eﬄux also appear erythromycin resistant
and clindamycin susceptible in in-vitro tests, such isolates
do not typically become clindamycin resistant during ther-
apy (11, 12).
Unlike constitutive (c) MLSB (cMLSB) resistance, in-
ducible (i) MLSB (iMLSB) resistance is not recognized in
conventional laboratory tests (8, 9). Inaccurate identifica-
tion of iMLSB resistance may lead to clinical failure of clin-
damycin therapy; conversely, labeling all erythromycin-
resistant staphylococci as clindamycin resistant prevents
the use of clindamycin in infections caused by truly clin-
damycin susceptible staphylococcal isolates (6, 8, 11).
The incidence of MLSB resistance varies significantly
according to geographical region, from hospital to hos-
pital, and age group (6, 12). On the other hand, the fre-
quency of iMLSB in the north west of Iran has not been
studied thoroughly. By using a simple disk approximation
test, namely D-test, microbiology laboratories can differ-
entiate isolates which are iMLSB resistant and harbor erm
genes from those that are truly sensitive to clindamycin
and show eﬄux pump mediated resistance as macrolide
and streptogramin B (MSB) or negative phenotype (due to
msrA gene) (6, 8, 9, 11, 12).
2. Objectives
The present study investigated the frequency of MLSB
resistance among clinical isolates of S. aureus isolated from
various teaching hospitals in the north west of Iran, in-
cluding MRSA and methicillin susceptible S. aureus (MSSA)
by phenotypic and genotypic methods and assessed resis-
tance to therapeutic agents which are recommended for
these isolates.
3. Methods
3.1. Isolation and Identification of Staphylococcus aureus
During a period of one year from February 2014 to
March 2015, all clinical specimens submitted to microbi-
ology laboratories of educational health care centers of
Tabriz University of Medical Sciences in the Northwest of
Iran were screened for presence of S. aureus isolates. Repet-
itive isolates from the same patient were not examined in
this study. The isolates were obtained from different speci-
mens of inpatients and outpatients such as: wound, blood,
urine, abscess, fistula and catheter aspirates, sputum and
other body fluids and were confirmed by standard micro-
biology tests (13). They were further confirmed by PCR as-
say for the presence of nuc gene in all the isolates (14). Two
hundred and fifteen isolates were collected and stored in
TSB broth supplemented by 30% glycerol at -70°C.
3.2. Antibiotic Susceptibility Testing
Antibiotic susceptibility test was performed as per
the clinical and laboratory standards institute (CLSI-2014)
guidelines (15), with a panel of following antibiotics (MAST,
Group Ltd, Merseyside, UK): oxacillin (1 µg), cefoxitin (30
µg), penicillin (10 U), gentamicin (10µg), erythromycin (15
µg), clindamycin (2 µg), rifampin (30 µg), ciprofloxacin (5
µg), trimetoprim-sulfametoxazol (1.25/23.75 µg), and line-
zolid (30 µg). The minimal inhibitory concentrations
(MICs) were determined by E-test on Mueller-Hinton’s agar
plates (MHA, Merck, Germany) for vancomycin accord-
ing to the manufacturer’s recommendations (Liofilchem,
Italy) and the breakpoints for resistance were those as de-
fined by the CLSI-2014. Staphylococcus aureus ATCC 25923,
S. aureus ATCC 29213, S. aureus ATCC 33591, Enterococcus fae-
calis ATCC 29212, and E. faecalis ATCC 51299 were used as the
control strains.
3.3. Disk Approximation Test (D-Test)
D-zone test was performed as per the CLSI 2014 guide-
lines (15). Briefly, a suspension of overnight growth of iso-
lates equivalent to 0.5 McFarland turbidity was inoculated
on MHA plates. For detecting inducible clindamycin re-
sistance, 15 µg erythromycin disks and 2 µg clindamycin
disks (MAST, Group Ltd, Merseyside, UK) were placed on
MHA plates (15 mm edge to edge) as part of a standard
disk diffusion test. Following overnight incubation at 35°C,
inducible clindamycin resistance was observed as flatten-
ing of zone towards clindamycin (D-shape), which indi-
cates the isolate has inducible clindamycin resistance (be-
cause of erm gene) (9). No flattening of zone towards
clindamycin indicates the isolate is erythromycin resistant
only (due to msrA gene). As an isolate demonstrated in-
ducible resistance, clindamycin was reported as resistant
(6, 9). Based on D-test results, S. aureus isolates were catego-
rized into four non-inducible and two inducible resistance
phenotypes according to a previous study (9).
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3.4. DNA Extraction
Briefly, DNA was extracted using dodecyl sulphate
sodium salt (SDS, Merck, Germany) - proteinase K (Cinna-
Gene, Tehran, Iran) method modified with N-cetyl-N, N, N-
trimethyl ammonium bromide (CTAB, Merck, Germany)
(3). The concentration of extracted DNA was confirmed by
Nano drop 1000 (NanoDrop, Wilmington, USA).
3.5. Identification of nuc, mecA, erm and msrA Genes by PCR
Confirmation of all S. aureus isolates was car-
ried out by PCR for amplification of nuc gene (279
bp) using primer pair (CinnaGene, Tehran, Iran,
nuc/F: 5’-GCGATTGATGGTGATACGGTT-3’ and nuc/R: 5’-
AGCCAAGCCTTGACGAACTAAAGC-3’) (14). PCRs were per-
formed in a final volume of 25 µL with an automated
thermal cycler (Eppendorf mastercycler gradient, Ger-
many) with the PCR cycling conditions which were as
follows: initial cycle at 94°C for 5 minute, followed by
37 cycles at 94°C for 1 minute, 55°C for 30 seconds, 72°C
for 1 minute and 30 seconds, and final extension cycle at
72°C for 3 minutes and 30 seconds. PCR products were
analyzed on 1.5% agarose gel, which was visualized under
ultraviolet illumination (Gel documentation, UVP, UK).
Negative controls for each used primer contained all the
components except template DNA. Staphylococcus aureus
ATCC 25923 and S. epidermidis ATCC 12228 were used as
positive and negative control strains, respectively.
Staphylococcus aureus isolates were confirmed as MRSA
based on the presence of mecA gene (310 bp) among our
isolates of S. aureus using primer pair (CinnaGene, Tehran,
Iran, mecA/F: 5’- GTAGAAATGACTGAACGTCCGATAA-3’ and
mecA/R: 5’-CCAATTCCACATTGTTTCGGTCTAA-3’) (3). PCR cy-
cling conditions were as follows: initial cycle at 94°C for 4
min, followed by 30 cycles at 94°C for 45 seconds, 56°C for
45 seconds, 72°C for 1 minute, and final extension cycle at
72°C for 7 minutes. Staphylococcus aureus ATCC 33591 and S.
aureus ATCC 25923 were used as positive and negative con-
trol strains, respectively.
Amplification of ermA (139 bp), ermB (142 bp),
ermC (190 bp), and msrA (163 bp) genes was car-
ried out according to previous studies (16, 17).
Oligonucleotide primers used for PCR were as
follows: ermA/F: 5’-TATCTTATCGTTGAGAAGGGATT-
3’, ermA/R: 5’-CTACACTTGGCTTAGGATGAAA-
3’, ermB/F: 5’-CTATCTGATTGTTGAAGAAGGATT-
3’, ermB/R: 5’-TTTACTCTTGGTTTAGGATGAAA–3’,
ermC/F: 5’-CTTGTTGATCACGATAATTTCC-3’, ermC/R:
5’-ATCTTTTAGCAAACCCGTATTC-3’, msrA/F:
5’-TCCAATCATTGCACAAAATC-3’, msrA/R: 5’-
AATTCCCTCTATTTGGTGGT-3’. PCR conditions were as
follows: Initial denaturation at 95°C for 3 minutes; fol-
lowed by 35 cycles at 95°C for 30 seconds, various anneal-
ing temperatures (62.8°C for ermA, 59°C for ermB, 58°C
for ermC, and 55°C for msrA) for 30 seconds, followed by
extension at 72°C for 45 seconds and final extension at 72°C
for 7 minutes. Staphylococcus aureus isolates with ermA,
ermC, ermB, and msrA genes and S. aureus strains (ATCC
25923 and ATCC 29213) were used as positive and negative
control strains, respectively.
3.6. Statistical Analysis
Data were analyzed by Chi-square test using SPSS 22.0
statistical software (SPSS Inc., Chicago, IL). Astatistically sig-
nificant difference was considered as P value < 0.05.
3.7. Ethical Approval
This work was approved by the ethics committee
of Tabriz University of Medical Sciences (reference No.
5/4/3978).
4. Results
A total of 215 isolates of S. aureus were collected from
various clinical specimens and identified by standard tests.
4.1. Molecular Tests
The nuc gene (279 bp) was amplified by all of our iso-
lates. PCR for mecA gene was performed on S. aureus iso-
lates that showed 87 (40.5%) as MRSA and 128 (59.5%) as
MSSA. The distribution of MRSA isolates was as follows: 63
(72.41%) from in-patients and 24 (27.59%) from out-patients
(P = 0.649), while for MSSA isolates it was 89 (69.53%) from
in-patients and 39 (30.47%) from out-patients (P = 0.649).
According to PCR results, 46 (21.40%) and 84 (39.06%) S.
aureus isolates were positive for presence of ermA and ermC
genes, respectively. Out of 215 isolates, thirty nine (18.14%)
showed both ermA and ermC genes. Although 6 (2.79%) iso-
lates were positive on D test, they were negative for the
presence of erm genes. All isolates were negative for the
presence of ermB and msrA genes (Figure 1). The distribu-
tion of above-mentioned genes among MRSA and MSSA iso-
lates is shown in Table 1.
4.2. Phenotypic Tests
The results of antimicrobial sensitivity test showed
that all isolates (100%) were susceptible to linezolid and the
majority of them (96.3%) were resistant to penicillin. The
results of antibiotic susceptibility testing for other antibi-
otics are shown in Table 2. The rates of resistance among
MRSA and MSSA isolates against studied antibiotics were as
follows: penicillin, 100% and 93.75% (P = 0.017); oxacillin,
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Figure 1. Separation of 142 and 163 Banding Patterns of ermB and msrA Genes on 1.5%
Agarose Gel
Lanes 1 to 3, isolates without ermB gene; lane 4, reagent control; lane 5, S. aureus ATCC
25923 as negative control, lane 6, control isolate with ermB gene; lane 7, Size marker
1000 bp DNA Ladder; lanes 8, control isolate with msrA gene; lane 9, S. aureus ATCC
29213 as negative control; lanes 10 to 12, isolates without msrA gene.
Table 1. Distribution of ermA and ermC Genes among D Positive Studied Isolatesa , b
Genes MRSA (n = 87) MSSA (n = 128) Total isolates (n
= 215)
ermA alone 44 (50.57) 2 (1.56) 46 (21.40)
ermC alone 67 (77.01) 17 (13.28) 84 (39.06)
ermA + ermC 38 (43.67) 1 (0.78) 39 (18.14)
Without ermA
and ermC
4 (4.60) 2 (1.56) 6 (2.79)
aValues are expressed as No. (%).
bNo ermB and msrA genes were detected in the present study.
89.7% and 0% (P = 0.000); cefoxitin, 96.6% and 0% (P =
0.000); clindamycin, 88.5% and 15.62% (P = 0.000); ery-
thromycin, 86.2% and 15.62% (P = 0.000); ciprofloxacin,
83.9% and 3.12% (P = 0.000); gentamicin, 83.9% and 0.78%
(P = 0.000); trimethoprim-sulfamethoxazole, 55.17% and
1.56% (P = 0.000); rifampin, 39.08% and 0% (P = 0.000), re-
spectively. Antibiotic resistance patterns of 87 MRSA iso-
lates are shown in Table 3. The isolates fell into 10 distinc-
tive antibiotic resistance profiles.
Seventy seven out of 87 MRSA isolates (88.50%) were re-
sistant to more than 3 antimicrobial agents, and thus they
were recorded as multidrug-resistant (MDR) (Table 3). The
MIC of isolates against vancomycin was in the range of 0.25
µg/mL to 6µg/mL and the MIC50 and MIC90 for the isolates
were 0.5 and 1 µg/mL, respectively. Only 3 MRSA isolates,
Table 2. Resistance Patterns of S. aureus Isolates Against Tested Antibiotics
Antibiotics S I R
Penicillin 8 (3.7) - 207 (96.3)
Oxacillin 137 (63.7) - 78 (36.3)
Cefoxitin 131 (60.93) - 84 (39.07)
Gentamicin 141 (65.6) - 74 (34.4)
Erythromycin 120 (56) - 95 (44)
Clindamycin 118 (55) - 97 (45)
Trimethoprim-sulfamethoxazol 165 (76.7) - 50 (23.3)
Ciprofloxacin 138 (64.2) - 77 (35.8)
Rifampin 181 (84.2) - 34 (15.8)
Linezolid 215 (100) - 0 (0)
Abbreviations: I, intermediate; R, resistant; S, sensitive.
which showed MICs equal to 6 µg/mL, were recorded as
vancomycin intermediate-resistant S. aureus (VISA). MRSA
isolates were resistant to antibiotics significantly more
than MSSA (P = 0.000) except for penicillin, linzeolide, and
vancomycin. All MRSA and MSSA isolates were susceptible
to linzeolide (P = 0.409) and vancomycin (P = 0.409, except
3 MRSA isolates).
Based on D test results, various phenotypes detected
among 215 isolates of S. aureus are shown in Table 4. Table 5
depicts the rate of inducible clindamycin resistance (ICR)
in MSSA and MRSA isolates. Though this rate was higher
in MSSA (11.71%) than MRSA (9.19%) isolates, this difference
was not meaningful (P = 0.557). In contrast, the rate of con-
stitutive MLSB resistance was significantly higher in MRSA
(79.31%) than MSSA (3.90%) isolates (P = 0.000). MSB pheno-
type was not detected in this study.
Our findings revealed that 75 (86.20%) of MRSA isolates
were resistant to erythromycin among whom 66 (88%) and
9 (12%) isolates were cMLSB and iMLSB, respectively. On the
other hand, 20 (15.62%) of MSSA isolates were resistant to
erythromycin, and cMLSB and iMLSB phenotypes were seen
in 5 (25%) and 15 (75%) isolates, respectively. Among 152 in-
patients and 63 out-patients, ICR phenotype was observed
in 14 (9.21%) and 9 (14.28%) isolates, respectively (P = 0.273).
5. Discussion
The emergence of VISA is a great concern and also an
alarm for clinicians to give a second thought to the usage
of this antibiotic (vancomycin) or finding an alternative
treatment such as MLSB antibiotics (2, 4-6, 8, 9, 17, 18). Un-
fortunately, misuses of MLSB antibiotics have led to an un-
usual increase in the rate of resistance to these antibiotics
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Table 3. Antibiotic Resistance Patterns of 87 Methicillin Resistant Staphylococcus aureus (MRSA) Isolates
Resistance Patterns No. (Identity of Isolates) Antibiotic Resistance Patterns MDRa or Non-MDR
R1 4 (14, 75, 111, 119) P, OX, FOX Non-MDR
R2 2 (132, 135) P, OX, FOX, GM, CC, SXT MDR
R3 39 (2 - 5, 8, 15, 25, 37, 41, 42, 44, 47, 61-63, 91, 98, 107, 114, 117, 118, 123, 124, 136, 140, 151,
152, 154, 156-158, 160, 162, 173, 175, 176-178, 209)
P, OX, FOX, GM, CC, E, CP, SXT
R4 26 (10, 11, 13, 16, 19, 22, 28, 40, 48, 57, 76, 83, 96, 97, 105, 153, 155, 159, 161, 174, 181, 182,
201-203, 206)
P, OX, FOX, GM, CC, E, CP, R MDR
R5 6 (60, 68, 74, 78, 125, 179) P, OX, FOX, GM, CC, E, CP, SXT, R MDR
R6 1 (192) P, OX, FOX, CC, E, CP, R MDR
R7 1 (7) P, FOX, CC, E, CP, SXT MDR
R8 2 (20, 147) P, FOX, CC, E MDR
R9 3 (109, 115, 150) P, FOX Non-MDR
R10 3 (39, 50, 51) P Non-MDR
Abbreviations: CC, clindamycin; CP, ciprofloxacin; E, erythromycin; FOX, cefoxitin; GM, gentamicin; OX, oxacillin; P, penicillin; R, rifampin; SXT, trimethoprim-
sulfamethoxazole.
aMultidrug-resistant (isolates that are resistant to more than 3 antimicrobial agents, 88.50% of the MRSA isolates are MDR).
Table 4. Inducible and Non-Inducible Phenotype of 215 S. aureus Isolates Based on D Testa
D Test Phenotypes Resistance Phenotypes CC Result E Result S. aureus (215 Isolates) D Test Description
D Inducible MLSB S R 13 (6.04) D shaped clear zone around CC disc proximal to E disc
D+ Inducible MLSB S R 10 (4.65)
D- MS or Neg. S R 0 Clear zone only around CC disc
R Constitutive MLSB R R 71 (33.02) Growth upto CC and E discs
HD Constitutive MLSB R R 3 (1.39) Two zones of growth around CC disc
S No resistance S S 118 (54.88) Clear zone around both discs
Abbreviations: CC, clindamycin; D, D zone test, E, erythromycin; HD, hazy D zone; Neg, Negative; R, resistant; S, sensitive.
aValues are expressed as No. (%).
Table 5. MLSB Resistance Phenotypes of S. aureus
a
Isolate Name Total Isolates Constitutive MLSB Inducible MLSB S Phenotype
S. aureus 215 74 (34.42) 23 (10.69) 118 (54.88)
MSSA 128 (59.5) 5 (3.90) 15 (11.71) 108 (84.37)
MRSA 87 (40.5) 69 (79.31) 8 (9.19) 10 (11.49)
aValues are expressed as No. (%).
especially to clindamycin (8, 9). Therefore, it is important
for microbiology laboratories to correctly recognize and
report whether an S. aureus isolate is truly clindamycin sus-
ceptible or not. This true result can be obtained by using
a simple disk agar diffusion test, described as D-zone test,
because this test can exclude inducible clindamycin resis-
tance (8, 9, 11, 12, 17).
In the present study, the prevalence of iMLSB, cMLSB,
MSB, and S phenotypes among all the S. aureus isolates was
10.69%, 34.42%, 0%, and 54.88%, respectively. The frequency
of ICR was in agreement with previous findings from Iran
and India (19-22). However, lower rates of ICR (5.2%, 5.3%,
and 8.64%) were reported by other researchers (23-25). In
contrast to our finding, the higher rates of ICR have been
reported (20.3%, 20.7%, 32.3%, and 33.3%) by other investiga-
tors (17, 26-28). Such differences in the ICR pattern could be
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due to differences in prescriptions of MLSB drug groups.
In contrast to many studies, our finding in this study
showed that the frequency of inducible resistance pheno-
type was higher in MSSA (11.71%) than MRSA (9.19%) isolates
(P = 0.557) (10, 17, 23-26). Similar to our study, in a study
from southeastern of Turkey it was shown that inducible
clindamycin resistant strains were more prevalent in MSSA
(10%) than MRSA (6.9%), nevertheless, this difference was
also not significant (P = 0.434) (29).
In the present study, constitutive clindamycin resis-
tance was seen in 74 (34.42%) S. aureus isolates that was
comparable with two studies from Iran and India (25, 30).
Other researchers have reported either much lower preva-
lence (12.9%, 16.6%, and 23.3%) or higher rates (36%, 37.5% and
40%) (17, 19, 23, 27, 31, 32). Our finding shows the preva-
lence of constitutive clindamycin resistance phenotype
was 79.31% in MRSA and 3.90% in MSSA isolates (P = 0.000).
This predominance has also been reported by most stud-
ies (20, 29). The reasons of above undulations among var-
ious reports are the MLSB resistance pattern which varies
widely among geographical region, age, source and type of
strains, susceptibility to methicillin, and even among med-
ical centers, and as previously mentioned, such differences
could be due to differences in the form of drug usage (6, 9,
11, 12).
Hazy D (HD) phenotype was detected in 3 (3.45%) MRSA
isolates. This type of resistance must be considered as R
phenotype and its rate has been reported rarely in different
countries (10). MSB or negative phenotype was not found
in our study and all the erythromycin resistant and clin-
damycin susceptible isolates showed inducible resistance
phenotype. The rates of MSB phenotype among S. aureus
isolates have been reported to vary from 5.7% to 44.8% in
other countries (19-21, 25-28, 31). These differences in the
rates of MSB phenotype which is related to msrA genes em-
phasize the importance of performing D-test for differen-
tiation of truly clindamycin susceptibility from iMLSB phe-
notype and selecting proper therapeutic agent.
In this present study, ermA and ermC genes were ob-
served in 46 (21.40%) and 84 (39.06%) isolates, respectively,
while much higher frequencies have been reported in
other Iranian studies (60.3% - 54.8% and 41.1% - 17.7%) (17, 33).
Other studies conducted in various parts of the world have
shown that ermA and ermC were responsible for the major-
ity of resistance to erythromycin among S. aureus isolates
(4, 34, 35). In some studies, ermA is predominant, while in
the others ermC is more prevalent than ermA genes (36, 37).
In contrast to our finding, in all the above-mentioned stud-
ies, the rate of ermA gene was more than the rate of ermC
gene. However, in agreement with our finding, a study
carried out in Denmark showed 16% and 84% of S. aureus
isolates were harboring ermA and ermC, respectively (37).
Spiliopoulou et al. (37) have reported in Greece that ermC
gene with 70% prevalence is the predominant genetic de-
terminant compared to ermA gene with 22%. This predom-
inance is probably due to the spread of distinctive clones
(which carry ermC gene) in the mentioned countries and
our region.
Based on the findings of our study and some other
studies, no ermB gene has been found in studied isolates of
S. aureus (17, 33, 38). But in 3 studies conducted in France,
Brazil, and Turkey, the frequency of ermB gene was 0.7%,
2.2%, and 8.3%, respectively (16, 39, 40). Our finding did
not show any msrA gene that is similar to the two available
studies from Iran (17, 33). However, different low rates of
msrA gene have been reported by other researchers (16, 38,
40).
A notable finding of the present study was the co-
presence of ermA and ermC in a significant number (39,
18.14%) of our isolates. In other studies, the presence of
both genes has been reported in their studied isolates with
different rates (16, 17, 33, 38). Six S. aureus isolates which had
iMLSB phenotype did not carry any of ermA and ermC genes,
therefore, other genes or factors may have a significant role
in resistance to erythromycin. Similar finding has been re-
ported in other studies from Iran and Turkey (16, 17, 33).
5.1. Conclusions
The rate of inducible resistance to clindamycin in S.
aureus isolates is relatively high in the north west of Iran.
Since isolates with inducible resistance may mutate and
change to constitutive resistance, for excluding inducible
clindamycin resistance, microbiology laboratories must
correctly recognize clindamycin susceptibility in S. aureus
isolates by using D-test. ICR frequency was higher in MSSA
than MRSA isolates. Our finding showed ermC as the pre-
dominant genetic determinant. This predominance is
probably due to the spread of distinctive clones (which
carry ermC gene) in our region.
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